Aptevo Therapeutics Initiates Phase 1b/2 RAINIER Trial To Evaluate Lead Candidate Mipletamig (APVO436) In Combination With Venetoclax And Azacitidine For Frontline AML; New Data Expected To Bolster Existing Efficacy Outcomes And Identify Recommended Phase 2 Dose
Portfolio Pulse from Benzinga Newsdesk
Aptevo Therapeutics has initiated a Phase 1b/2 RAINIER trial to evaluate its lead candidate Mipletamig (APVO436) in combination with Venetoclax and Azacitidine for frontline acute myeloid leukemia (AML). The new data from this trial is expected to bolster existing efficacy outcomes and identify the recommended Phase 2 dose.
August 13, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aptevo Therapeutics has initiated a Phase 1b/2 trial for its lead candidate Mipletamig (APVO436) in combination with Venetoclax and Azacitidine for frontline AML. The trial aims to bolster existing efficacy outcomes and identify the recommended Phase 2 dose.
The initiation of the Phase 1b/2 trial for Mipletamig (APVO436) is a significant step for Aptevo Therapeutics. Positive data from this trial could enhance the drug's efficacy profile and lead to a recommended Phase 2 dose, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100